Longboard Pharmaceuticals Performance
| LBPHDelisted Stock | USD 59.98 0.00 0.00% |
Longboard Pharmaceuticals holds a performance score of 14 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.12, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Longboard Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Longboard Pharmaceuticals is likely to outperform the market. Use Longboard Pharmaceuticals downside variance, and the relationship between the treynor ratio and kurtosis , to analyze future returns on Longboard Pharmaceuticals.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Longboard Pharmaceuticals are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating basic indicators, Longboard Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 10.8 M |
Longboard |
Longboard Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 3,291 in Longboard Pharmaceuticals on September 22, 2024 and sell it today you would earn a total of 2,707 from holding Longboard Pharmaceuticals or generate 82.25% return on investment over 90 days. Longboard Pharmaceuticals is currently generating 1.3855% in daily expected returns and assumes 7.657% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Longboard, and 73% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Longboard Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Longboard Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Longboard Pharmaceuticals, and traders can use it to determine the average amount a Longboard Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.181
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | LBPH | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.66 actual daily | 68 68% of assets are less volatile |
Expected Return
| 1.39 actual daily | 27 73% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Longboard Pharmaceuticals is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Longboard Pharmaceuticals by adding it to a well-diversified portfolio.
Longboard Pharmaceuticals Fundamentals Growth
Longboard Stock prices reflect investors' perceptions of the future prospects and financial health of Longboard Pharmaceuticals, and Longboard Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Longboard Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 2.06 B | ||||
| Shares Outstanding | 34.44 M | ||||
| Price To Book | 8.51 X | ||||
| EBITDA | (56.75 M) | ||||
| Cash And Equivalents | 87.42 M | ||||
| Cash Per Share | 5.09 X | ||||
| Total Debt | 475 K | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 7.05 X | ||||
| Cash Flow From Operations | (50.87 M) | ||||
| Earnings Per Share | (2.25) X | ||||
| Total Asset | 50.7 M | ||||
| Retained Earnings | (140.56 M) | ||||
About Longboard Pharmaceuticals Performance
By evaluating Longboard Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Longboard Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Longboard Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Longboard Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. Longboard Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people.Things to note about Longboard Pharmaceuticals performance evaluation
Checking the ongoing alerts about Longboard Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Longboard Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Longboard Pharmaceuticals is not yet fully synchronised with the market data | |
| Longboard Pharmaceuticals is way too risky over 90 days horizon | |
| Longboard Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Longboard Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (54.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Longboard Pharmaceuticals currently holds about 87.42 M in cash with (50.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.09. | |
| Over 99.0% of the company shares are owned by institutional investors |
- Analyzing Longboard Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Longboard Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Longboard Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Longboard Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Longboard Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Longboard Pharmaceuticals' stock. These opinions can provide insight into Longboard Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Longboard Stock
If you are still planning to invest in Longboard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Longboard Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |